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Beta-amyloid (Aβ) immunotherapy is a promising intervention to slow Alzheimer’s disease (AD).
Aging dogs naturally accumulate Aβ and show cognitive decline. An active vaccine against
fibrillar Aβ 1–42 (VAC) in aged beagles resulted in maintenance but not improvement of
cognition along with reduced brain Aβ. Behavioral enrichment (ENR) led to cognitive benefits but
no reduction in Aβ. We hypothesized cognitive outcomes could be improved by combining VAC
with ENR in aged dogs. Aged dogs (11–12 years) were placed into 4 groups: (1) control/control
(C/C); (2) control/VAC (C/V); (3) ENR/control (E/C); (4) ENR and VAC (E/V) and treated for 20
months. VAC decreased brain Aβ, pyroglutamate Aβ, increased CSF Aβ42 and BDNF RNA levels
but also increased microhemorrhages. ENR reduced brain Aβ and prevented microhemorrhages.
The combination treatment resulted in a significant maintenance of learning over time, reduced Aβ
and increased BDNF mRNA despite increased microhemorrhages, however there were no benefits
to memory. These results suggest that the combination of immunotherapy with behavioral
enrichment leads to cognitive maintenance associated with reduced neuropathology that may
benefit people with AD.
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Alzheimer’s disease (AD) is associated with progressive cognitive decline and the
accumulation of senile plaques and neurofibrillary tangles (Mirra, et al., 1991). Senile
plaques contain beta-amyloid (Aβ), which is a peptide thought to play a causative role in the
disease (Hardy and Higgins, 1992). Several therapeutics in clinical trials are designed to
reduce the production and deposition or improve clearance of Aβ (Selkoe and Schenk,
2003). Immunization with fibrillar Aβ 1–42 in mouse models of AD can reduce or prevent
deposition of Aβ (Morgan, et al., 2000;Schenk, 1999) and improve memory (Janus, et al.,
2000;Morgan, et al., 2000;Wilcock, et al., 2009;Wilcock, et al., 2004).

Author Manuscript

Clinical trials in patients with AD have led to only modest positive outcomes, or potentially
serious adverse events in response to both active (Aβ peptide with a conjugate to stimulate
an immune response) or passive (administration of anti-Aβ antibodies) (Wisniewski and
Goni, 2015). Using an active vaccine, AD patients who came to autopsy showed reduced Aβ
(Ferrer, et al., 2004;Gilman, et al., 2005;Hock, et al., 2003;Masliah, et al., 2005;Nicoll, et
al., 2003). Notably, using an active vaccine approach, decreased Aβ pathology persisted 5
years after the last vaccination (Holmes, et al., 2008), although reduced brain Aβ did not
slow AD progression. A recent Phase 3 clinical trial using solanezumab (a humanized
version of a mouse antibody m266) in a passive vaccine approach suggest benefits in those
patients with mild AD, strongly suggesting a prevention approach might be more
appropriate for these therapies (Doody, et al., 2014;Karran and Hardy, 2014). Adverse
effects associated with anti-Aβ immunotherapy include edema and microhemorrhages in the
case of passive vaccines (Sperling, et al., 2012;Wilcock and Colton, 2009) and aseptic
meningoencephalitis with active vaccine approaches (Boche and Nicoll, 2008). Despite
these, both are still being explored in a number of clinical trials (Wisniewski and Goni,
2015).

Author Manuscript

We have seen similar cognitive and Aβ outcomes to human clinical trials using an active
anti-Aβ immunotherapeutic approach in the canine model of human brain aging, which
naturally produces human-type Aβ (Cotman and Head, 2008). Aged canines show a decline
in memory and learning and a corresponding increase in Aβ pathology (Cotman and Head,
2008). In a previous study, animals were immunized with fibrillar Aβ1–42 for 2 years.
Although we found little improvement in cognition, we did find evidence for maintenance of
prefrontal function (reversal learning) (Head, et al., 2008). Brain Aβ was significantly
reduced in vaccinated animals. Based on our work with the previous canine study and the
clinical trials outcomes, we hypothesized that clearing preexisting Aβ was insufficient to
restore neuronal function. In both dogs (Azizeh, et al., 2000;Frost, et al., 2013) and humans
(Fonseca, et al., 1999;Frost, et al., 2013), Aβ can be deposited over many years, which
suggests neurons are chronically exposed to Aβ toxicity. Thus, we introduced a second arm
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to the study, behavioral enrichment (ENR), which leads to cognitive benefits in aged canines
through mechanisms independent of Aβ reduction (Fahnestock, et al., 2010;Siwak-Tapp, et
al., 2008). This combination approach, targeting pathways that can reduce Aβ and restore
neuronal function, may be more effective than either intervention alone.
We tested the hypothesis that cognitive outcomes from Aβ vaccination could be improved
with the addition of behavioral enrichment. Thus, a group of aged beagles were assigned to
one of 4 groups: 1) control/control (C/C); (2) control/vaccine (C/V); (3) behavioral
enrichment/control (E/C); (4) behavioral enrichment and vaccine (E/V). Over the duration of
the study, cognition was assessed, antibody titers were measured, and cerebrospinal fluid Aβ
was assayed. At the end of the study, brain tissue was collected to measure Aβ,
cerebrovascular pathology, brain derived neurotrophic factor and synaptophysin RNA levels.

Author Manuscript

Materials and Methods
Animals

Author Manuscript

As shown in Table 1, the longitudinal study started with 34 beagles (10.5 – 13.6 years –
Table 1): 31 from Lovelace Respiratory Research Institute (LRRI – Albuquerque, NM) and 3
from Harlan (Riglan Farms, Inc, Mount Horeb, Wisconsin). Dogs were housed in pairs
(n=12) or singly (n=22) in kennel buildings with indoor/outdoor runs measuring 91 cm x
600 cm, which were the same kennels as used in previous studies (Head, et al.,
2008;Milgram, et al., 2005). Some dogs were required to be housed singly as they were
aggressive towards other dogs. However, the number of animals in each type of housing was
similar across groups (Table 1). The outdoor portions of the kennels were separated by chain
link fencing allowing animals to see neighboring dogs and interact. Housing conditions were
randomized across treatment conditions. Dogs were fed Harlan Teklad Global Diet (25%
protein - Teklad Pioneer Lab Diets, Madison, WI) once daily and water was available at all
times. All animals were thoroughly examined prior to inclusion in the study and were
determined to be in good health. Examinations included physical examination, neurological
examination and analysis of blood biochemistry values. All procedures were conducted in
accordance with LRRI approved animal protocols and the NIH Policy on Humane Care and
Use of Laboratory Animals.
Overall Study Design

Author Manuscript

The cognitive testing procedures from the previous vaccination study in dogs were repeated
in the current study to allow direct comparisons between experiments (Head, et al., 2008).
Dogs were first given a series of baseline cognitive tests to train them to work in the
apparatus and to assess learning and memory function prior to the initiation of treatment. No
food deprivation is required for any of the cognitive testing procedures as animals are
motivated to acquire the food rewards. Subsequently, the vaccine and behavioral enrichment
protocols were implemented. Dogs in the behavioral enrichment condition were tested
throughout the treatment period as cognitive enrichment was a component of the study. In
contrast, dogs provided with only the vaccine were given cognitive testing after ~7 (10
injections) and 16 (19 injections) months of follow-up to assess longitudinal cognitive
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responses. At the end of the study, the brains of all treated animals (C/C, E/C, C/V, E/V)
were used to measure neurobiological outcomes.
Baseline Cognitive Testing

Author Manuscript

The testing apparatus has been described previously (Milgram, et al., 1994) and was a 0.609
x 1.15 x 1.08 m wooden box constructed from press board coated with melamine. The box
was equipped with a sliding black Plexiglas tray containing 3 food wells. Vertical stainless
steel bars, which could be adjusted to provide openings appropriate for individual dog sizes,
served as the front of the box. The experimenter sat behind a barrier that is hinged to allow a
sliding tray to be pushed either towards or out-of-view of the dog. A 60W light was placed
above the presentation tray to light the objects. Data acquisition was controlled using a
customized program (MetaCog Testing Systems, New Westminster, B.C., Canada). One
teaspoon (approximately 4 mls) of wet dog food was formed into a ball and served as the
food reward. Each dog was given either 10 or 12 trials a day (depending on the task) with
trials separated by a 30 sec intertrial interval.

Author Manuscript
Author Manuscript

Dogs were tested 5 days a week. Dogs were first given an object discrimination and reversal
learning task. The first test session was used to establish object preferences. On each trial,
the hinged door of the barrier separating the tester and the dog was raised, and the
presentation tray was pushed forward. The left and right food wells were covered by the two
objects. The food reward was placed inside both the left and right food wells beneath each
stimulus. Dogs were required to displace an object to obtain the hidden reward. Ten trials
were given with two objects presented simultaneously (yellow plastic coffee jar lid and blue
plastic Lego block) and with both objects baited. The objects appeared randomly 5 times
each on the left or right side. The preferred object was whichever object was chosen more
frequently (i.e. 6 or more times). Subsequently, the preferred object was used as the positive
stimulus. After establishing preferences, each subject was given 10 daily trials with the food
reward located beneath the designated positive object. To prevent the dogs from using
olfactory cues, the food odor was smeared over both wells and a piece of food was pressed
inside the negative stimulus such that the dog could smell it but not see it or eat it. A correct
response was recorded when dogs approached and displaced the positive stimulus. An error
was committed if dogs chose the negative object. One correction per test session was
allowed and subsequent errors resulted in an immediate withdrawal of the tray leaving the
dog unrewarded. Dogs were trained until one of two criterion levels was met: 9/10 correct on
one day or 8/10 correct on two consecutive days. An additional 3 days of testing was
provided to ensure that animals maintained an average of 70% or better correct. A maximum
of 400 trials were given if a dog could not reach criterion. After dogs had reached criterion
in the object discrimination problem, the reward contingencies of the positive and negative
stimuli were reversed. Testing was continued on this task until the same criterion as for the
object discrimination test was met. All other testing procedures were identical to those used
with object discrimination learning.
Following discrimination learning, dogs were given a spatial non matching to position
memory task as described in our previous study (Head, et al., 2008). To assess spatial
acquisition and memory, we used a 2- choice non matching to position task. Animals were
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first shown a single red Lego block covering either the left or right food wells. Animals
displaced the object on one side (e.g. L) to obtain the reward. A 5-second delay interval
followed, after which, animals were shown two identical red Lego blocks with the reward
hidden under the object on the side not rewarded previously (e.g. R). Dogs were given 10
trials per day with a 30 second intertrial interval and were tested for 40 days. During this 40day period, when criterion was met at a 5-second delay, the delay was progressively
increased to 10, 20, 30, 50, 70 and then 90 seconds. Two scores were derived from this
learning phase of the task: maximal memory and total number of errors to reach criterion at
the 5-second delay. Subsequently, animals were given 20 days of a variable delay problem.
In this task, used to assess working memory, animals were exposed to delays of either 20, 70
or 110 seconds on each day of testing. The order of the delay interval presentation was
random but each delay appeared 4 times/day and 12 trials were given each day. Accuracy
scores for each delay interval were calculated as a measure of spatial working memory and
used for repeated measures comparisons after treatment was started.

Author Manuscript

The total errors made for discrimination and reversal learning and for acquisition of the
spatial memory task were summed and dogs were ranked according to these total error
scores.
Aβ Vaccine

Author Manuscript

Fibrillar Aβ was prepared by adding 500 μl of sterile phosphate buffered saline (PBS pH
7.5) to 0.5 mg of peptide (provided by Dr. Charles Glabe, University of California at Irvine,
Irvine, CA), the sample was vortexed, and incubated overnight at 37°C in a water bath prior
to conjugation with the adjuvant. To prepare Aβ for immunization, each dog received 0.5 mg
of fibrillar Aβ (500 μl) that was added to 50 μl of 2% aluminum hydroxide (alum)
suspension (Accurate Chemical, Westbury, NY) and 450 μl of PBS and vortexed. All
animals that did not receive fibrillar Aβ 1–42 were given alum injections. Animals were
immunized subcutaneously in the back of the neck and monitored for adverse reactions.
After 2 weeks, animals were boosted with an additional injection followed by monthly
injections thereafter. The rationale for using an active vaccine approach was twofold: (1) to
use an identical vaccination approach as in our previous study to confirm and extend our
results; (2) a passive vaccine approach was prohibitive in terms of the volumes required and
the infusion process.
Behavioral Enrichment

Author Manuscript

Dogs in the behavioral enrichment group were given two 20-min walks outdoors in groups
of 3–4 animals each week. Play toys were rotated through their kennels on a weekly basis.
Cognitive enrichment involved additional testing procedures including: landmark
discrimination learning (1 month of treatment), oddity discrimination learning (4.3 months
of treatment) and a retest on landmark discrimination after ~15 months of treatment (See
Table 2 – more detailed descriptions to follow). For these cognitive tasks, only dogs
receiving behavioral enrichment were included. In a previous study, although the kennels
were identical, behavioral enrichment also included pair housing as compared to single
housing, but this was not possible in the current study given the number of animals that
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required single housing (Milgram, et al., 2005). Table 1 shows the number of animals in
each group that were singly housed.
Treatment Groups
Animals were assigned to one of four treatment groups balancing for baseline cognitive test
scores, sex, and age. All control animals received alum only as the injection while those
receiving the active vaccine were injected with fibrillar Aβ1–42 mixed with alum. These
groups included 1) control/control (n=8; C/C); (2) control/vaccine (n=8; C/V); (3)
behavioral enrichment/control (n=8; E/C); (4) behavioral enrichment and vaccine (n=10;
E/V). (Table 1). The study timeline is provided in Table 2.
Enrichment Task - Landmark Discrimination and Variable Landmark Test

Author Manuscript
Author Manuscript

The landmark discrimination task and variable landmark discrimination task represent tests
of spatial attention (Milgram, 1999;Milgram, et al., 2002). The first phase, Landmark 0,
involved showing animals two identical objects (wooden blocks) with a third object, the
landmark, placed on top of the object associated with a food reward. The correct response
was to select the object associated with the landmark. Animals were trained until criterion
was met, either by obtaining a score of 9/10 on one day or 8/10 on two consecutive days of
testing. A maximum of 40 days (400 trials) was given for all of the landmark tasks. In the
next phase of testing, the landmark was moved at successively greater distances (1, 4 or 10
cm) away from the reward object with animals required to meet criterion before progressing
to testing with a larger landmark distance. Animals that could not solve the problem at any
of the longer distances within 400 trials stopped testing on this stepwise protocol. Once all
animals had been tested out to a 10 cm distance on the landmark discrimination task or had
reached the maximum number of trials for a single distance, all animals were given a
variable landmark distance test. In this test, animals were given 12 trials per day with the
landmark being placed 1, 4 or 10 cm away from the correct object. These three distances
appeared for 4 trials per day with 12 trials/day in total and dogs were given a total of 20 days
of testing (240 trials).
Landmark discrimination learning was initiated after animals had been immunized twice
(initial, 2 weeks), which was 1 month into the treatment phase of the study. In previous
studies, the landmark task and the variable landmark procedure were age sensitive and
improved in aged dogs with behavioral enrichment (Milgram, 1999;Milgram, et al., 2002).
Following landmark discrimination learning, the variable landmark task was administered
for 20 days. After 15.2 months of treatment (18 immunizations), dogs were given another 20
days of variable distance landmark testing as described previously.

Author Manuscript

Enrichment Task - Oddity Discrimination
After 4.3 months of treatment and 5 immunizations, dogs were given the next behavioral
enrichment task, oddity discrimination learning, a measure of complex learning ability
(Milgram, et al., 2002). In previous studies, the oddity discrimination task was age sensitive
and distinguished animals receiving behavioral enrichment from controls (Cotman, et al.,
2002;Milgram, et al., 2005). This task involved 4 sets of 3 objects. Two objects of each set
were identical and one was novel. Animals were shown the first set and all 3 objects
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simultaneously, with a food reward hidden under the novel object. Dogs were given 12 trials
per day with the location of the food reward appearing once in each of the 3 food wells each
day. Once dogs learned the first problem, the next set of objects was used. The dogs were
required to reach criterion levels of responding from each object set prior to moving to the
more difficult object sets. Animals that failed to learn one of the oddity problems within 40
days of testing were stopped. The similarity between the odd object and the two identical
object increased with each problem set such that the last problem, oddity 4 was the most
difficult to discriminate.
Cognitive Outcomes Across All Treatment Groups

Author Manuscript

At pre-determined intervals, all dogs on study were administered tests of size and black/
white discrimination learning, size and black/white reversal learning and spatial memory
testing (Table 2). This allowed comparison across all 4 groups to detect synergistic effects of
the combined treatment. Dogs were included in each cognitive test analysis if they
completed that task. If a dog had to be removed from the study, and did not complete a task,
the scores were not included for that task in the data analysis.
Size Discrimination and Reversal Learning
After animals were treated for a period of 7.6 months and had received 10 immunizations,
they were given a size discrimination and reversal problem. The procedures were identical to
those used during baseline testing except the objects differed in size (one red wooden block
vs 2 wooden blocks stacked) (Milgram, et al., 2005).
Black/White Discrimination and Reversal Learning

Author Manuscript

After animals were treated for a period of 16.1 months and had received 19 immunizations,
they were given a black/white discrimination and reversal problem. The procedures were
identical to those used during baseline and size discrimination testing except the objects
were either a black or white lego block (Milgram, et al., 2005).
Spatial Learning and Memory

Author Manuscript

At two time points during the study, a 3-choice spatial memory task was used. The 3-choice
delayed non matching to position task has been described previously (Chan, et al., 2002) and
is sensitive to benefits of an antioxidant diet and behavioral enrichment with minimal
practice effects (Milgram, et al., 2005). Dogs were first shown a single red Lego block
covering either the left, right or center food wells. Once the object was displaced and the
reward obtained, a 5-second delay interval followed. After the delay, animals were shown 2
identical red Lego blocks, one covering the well seen previously, and the other covering one
of the two remaining food wells. The correct response was to select the object covering the
novel food well. Dogs were given 50 days of testing with 12 trials/day with the location of
the reward appearing 4 times each in the 3 food wells. During the 50 days of testing, if an
animal reached criterion at the 5-second delay, the delay was increased by 10 second
increments. This was continued over the 50 days of testing with gradually increasing delay
intervals. Following incremental delay interval increases over a 50-day period, dogs were
given a variable delay procedure for 20 days. As with the 2-choice spatial memory task,
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dogs would be exposed to either a 20, 70, or 110 second delay in a single day of testing.
Accuracy scores for each delay interval were calculated as a measure of spatial working
memory. Animals were tested at two time points, the first was after 11.9 months of treatment
and 14 immunizations and the second after 18.1 months of treatment and 21 immunizations.
Blood and Cerebrospinal Fluid Samples

Author Manuscript

Blood was collected from individual animals at baseline, 2 weeks, 1, 2, 3, 4, 5, 6, 12, 18 and
23 months after the first vaccination immediately prior to injections of the vaccine. Blood
was collected by jugular venipuncture for both serum (10mL) and plasma (10mL in EDTA).
Cerebrospinal fluid (CSF) samples were taken at baseline, after 12 months of treatment, and
19.6 months of treatment immediately prior to necropsy. For CSF sampling, dogs were
anesthetized with isoflurane and placed in lateral recumbency. The dorsal head and neck
area was clipped and aseptically prepared, and a spinal needle was advanced into the
cerebellomedullary cistern to collect approximately 1.5mL of CSF.
Necropsy and Brain Tissue Preparation
At the end of the study, following blood collection, anesthesia was induced and CSF
collected. Subsequently, pentobarbital-based euthanasia solution was infused intravenously.
Once heart sounds could no longer be auscultated, the brain was rapidly removed. The left
hemisphere was placed in 4% paraformaldehyde at 4°C for 72–80 h before transfer to PBS,
pH 7.4, with 0.02% sodium azide and stored at 4°C. The right hemisphere was sectioned
coronally and flash frozen to −80°C. The following subregions were dissected for each
outcome measure: prefrontal cortex (PFCTX), parietal cortex (PCTX), and occipital cortex
(OCTX).

Author Manuscript

Serum Titers
Aβ 1–42 antibody response was measured over nine time points of the study by enzymelinked immunosorbent assay (ELISA) (Head, et al., 2008).
CSF and Brain Aβ ELISA

Author Manuscript

Beta amyloid (1–40, 1–42, and total) was measured in CSF and tissue by sandwich ELISA.
Aβ was extracted from frozen tissue measured as previously described (Head, et al.,
2010;Murphy, et al., 2010). Briefly, frozen PFCTX, PCTX) and OCTX were extracted first
in PBS, then sodium dodecyl sulfate (SDS) and last, formic acid (FA). Antibodies Ab42.5
(human sequence Aβ1–16) for Aβ 1–40 capture, and 2.1.3 (end specific for Aβ 1–42) were
used. Biotinylated 13.1.1 (end specific for Aβ1–40) or 4G8 (human sequence Aβ 17–24,
Covance, Dedham, MA) were used to measure total levels of Aβ 1–40 and Aβ 1–42 in CSF
and in each brain fraction (PBS, SDS, and FA).
Aβ Plaque Load
Tissue was stained for Aβ plaques using previously published methods (Head, et al., 2008)
and anti-Aβ 42 (Invitrogen, Carlsbad, CA; 1:500, raised against Aβ36–42), 6E10 (Aβ1–16,
Covance, Dedham, MA; 1:1000), and PyroGlu3 (Novus Biological, Littleton, CO; 1:500)
antibodies. Tissue was pre-treated in 90% formic acid for 4 min (Kitamoto, 1987).

Neurobiol Aging. Author manuscript; available in PMC 2018 January 01.

Davis et al.

Page 9

RNA Studies

Author Manuscript

PCTX and OCTX were available for RNA studies of the levels of brain derived neurotrophic
factor. The methods have been published previously (Wilcock, et al., 2015). Briefly, frozen
brain tissue was pulverized using a mortar and pestle on dry ice with liquid nitrogen, and the
frozen pulverized tissue was stored at −80°C. RNA was extracted from approximately 80mg
frozen pulverized tissue using the Trizol Plus RNA Purification System (Life Technologies,
Grand Island NY) according to the manufacturer’s instructions. RNA was quantified using
the Biospec Nano spectrophotometer (Shimadzu, Columbia MD) and cDNA was reverse
transcribed using the cDNA High Capacity kit (Applied Biosystems, Foster City CA)
according to the manufacturer’s instructions. Real-time PCR was performed using Taqman
gene expression probe AB105074.1 (PMID NM_001002975.1) (Applied Biosystems, Foster
City CA). Gene expression data were normalized to 18S rRNA expression. Fold-change was
determined using the 2(delta delta Ct) method (Livak and Schmittgen, 2001).

Author Manuscript

Prussian Blue Staining
Prussian blue staining was used to identify microhemorrhages in PFCTX and OCTX tissue
for all study cases using methods based on previous studies (Wilcock, et al., 2004).
Image Analysis for Plaque Load and Prussian Blue Counts

Author Manuscript

To quantify the extent of Aβ plaque labeling, images were captured using ImagePro 6.3 with
an Olympus Q-Color 5 camera on an Olympus BX51 microscope at 20x objective
uniformly, five of the superficial layers and five of the deep layer for a total of 10 fields/
section. One section from each of the brain regions indicated for each dog was quantified in
this way. Quantification was done by image analysis using ImageJ to yield load values, the
percent area occupied by positive labeling similar to our previous report (Head, et al., 2008).
Quantification of Prussian blue staining was by counting microhemorrhages in each tissue
section using a 20X objective and counting within 10 fields/section. Prussian blue labeling
within 2 cell diameters of a blood vessel was considered a microhemorrhage. Counts were
totaled for each animal in each of the brain regions (Wilcock, et al., 2004).
Studies in Archived Brain Tissues from Dogs for Plaque Load and Prussian Blue
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We were interested in estimating the burden of Aβ pathology and microhemorrhages in our
dogs prior to the start of treatment to characterize changes in pathology over time and with
immunotherapy/behavioral enrichment. These dogs are referred to as the pre-treatment
animals. We selected 10 dogs that ranged in age from 10.8 to 13.5 years to compare changes
in plaque loads and number of microhemorrhages before treatment to 19 months of
treatment in a cross-sectional approach. These pretreatment dogs had no previous treatment
or cognitive testing. Tissue for the pretreatment dogs was collected and stored (in PBS with
sodium azide at 4°C) using the same methods as the experimental dogs.
Immunohistochemistry was used to measure total Aβ, Aβ 42, and PyroGlu3 plaque loads in
the PFCTX and PCTX. Prussian Blue staining was used to count the number of
microhemorrhages in the PFCTX and OCTX regions of the brain. All sections from the
pretreatment dogs and the current study samples were run in parallel to reduce variability as
a consequence of multiple immunohistochemistry experiments.
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Group comparisons for each outcome measure used several approaches depending on the
groups being compared and if there were repeated measures involved. ANOVA was used to
compare all 4 treatment groups (C/C, E/C, C/V, E/V) groups on baseline cognitive test
scores to ensure they were balanced with respect to error scores. T-tests were used to
evaluate differences due to vaccine treatment in dogs assigned to behavioral enrichment
(landmark test, oddity test) comparing the E/C and E/V groups. A repeated measures general
linear models approach including all 4 groups was used to compare the main effects of
vaccine alone, the behavioral enrichment alone, and to test the interaction (combination
treatment group) for changes in Aβ antibody serum titers. A generalized linear mixed model
(GLMM) for a repeated measures design was used to compare repeated measures on CSF
Aβ and cognitive error scores among the four treatment groups corresponding to the visual
discrimination and reversal tasks: object, size, and black/white. In all the analyses, cognitive
error scores (both discrimination errors and reversal errors) were assumed to follow a
Poisson distribution. An ANOVA was used to compare all 4 treatment groups (C/C, E/C,
C/V, E/V) groups on brain Aβ measures. For microhemorrhage counts, we used a chi-square
test to compare groups as this was a nonparametrically distributed outcome measure

Author Manuscript

While on study, 11 animals required euthanasia at different time points for medical issues
unrelated to the treatments that could not be managed without discomfort. Given the age of
the animals at the start of the study (~11–12 years) and their age at the end of the study (>13
years), this is not unexpected as the median age at death of beagles in this colony is 13.2
years (i.e. 50% of the animals are typically lost) (Lowseth, et al., 1990). Cognitive test
scores were included in the analysis if they had completed the task prior to death. Only dogs
that completed the study (including animals that could not be cognitively tested but
maintained on treatment) were included in the neurobiological outcome measures analyses.
Missing scores due to death were assumed to occur at random, while missing scores due to
not learning the black-white reversal task were assigned the maximum value of given chance
levels of performance (value 190 for all tasks). Statistical significance for omnibus tests was
determined at the 0.05 level. Post hoc comparisons used the Bonferroni or LSD correction.

Results

Author Manuscript

At baseline, there were no significant differences between groups for scores on object
discrimination learning (F(3,33=0.56 p=0.64) or object reversal learning (F(3,33)=0.03
p=0.99) indicating that animals were well-matched on the basis of associative learning and
executive function. Spatial learning scores were equivalent across the 4 groups
(F(3,33)=0.48 p=0.70). Spatial memory (20s, 70s, 110s) was also evenly matched across
groups at baseline with all showing a significantly reduced accuracy with increasing delays
(F(2,56)=5.94 p=0.005) but no main effects of behavioral enrichment (ENR - (F(2,56)=0.19
p=0.83), the vaccine (VAC -(F(2,56)=1.40 p=0.26), nor a group by delay interaction
(F(2,56)=1.03 p=0.37).
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To determine if the anti-fibrillar Aβ given to VAC treated animals induced an immune
response, we measured fibrillar Aβ1–42 antibody titers (Figure 1A). Fibrillar Aβ antibody
titers significantly increased over time in VAC animals (F(1,19)=13.6 p=0.002). No main
effect of ENR was seen on antibody titers (F(1,19)=2.0 p=0.17). Further, there was no
interaction between the two treatments (F(1,19)=1.82 p=0.19). .
Landmark Discrimination Learning

Author Manuscript

All dogs receiving ENR were given the landmark discrimination task. A significantly higher
error score was observed at the 1 month test in the dogs provided with the vaccine and
behavioral enrichment (E/V) relative to the dogs receiving behavioral enrichment (E/C)
alone (t(16)=2.7 p=0.016)(data not shown). However, based on our previous research, rather
than the vaccinated dogs doing more poorly, this effect was due to significantly lower error
scores in all dogs, particularly in the E/C group compared to previous studies of similarly
aged dogs (Milgram, et al., 2002). No other group differences were noted in landmark 1, 2
or 4 at either time point. The variable distance landmark test was conducted for a period of
20 days with 1, 2 or 4 cm distances appearing each day. The total number of errors made and
accuracy during the 20 days of testing was not different between the E/V and E/C groups
(data not shown).
Oddity Discrimination Learning

Author Manuscript

After 4.3 months of VAC treatment, a comparison was made between the E/V and E/C dogs
on the oddity task. In a repeated measures analysis (4 oddity tasks) using only dogs (n=15)
that were able to reach criterion levels of responding on all tasks there was a significant main
effect of the task (F(3,39)=4.75 p=0.006) suggesting increasing difficulty as was intended,
but no treatment group by oddity task interaction (F(3,39)=0.39 p=0.76). Overall there were
no treatment group differences (F(1,13)=3.41 p=0.088) (data not shown).
Repeated Visual Discrimination and Reversal Learning

Author Manuscript

To detect any treatment effects over time, a possible maintenance of function, and a
synergistic effect of the ENR on VAC, we compared baseline object discrimination to size
discrimination (7.6 months of treatment) and to black/white discrimination (16.1 months of
treatment) only in animals able to reach criterion for all 3 tasks (Figure 1B). Discrimination
learning errors over time showed a highly significant treatment group by time interaction (P
< 0.0001). Post hoc comparison of the treatment effects shows that for each treatment group
the three tasks differ from one another. For object and size discrimination, there was no
significant difference among the 4 groups. For the black/white discrimination task, the effect
of time for the combination group (E/V) is significantly smaller than the effects for C/C and
C/V groups (P =0.03 for each comparison) but only marginally smaller than the effect for
E/C (P = 0.054). The results of treatment on discrimination learning over time indicate that
the combination treatment group shows a synergistic maintenance of cognition over time.
Errors on the repeated reversal tasks revealed a highly significant treatment group by time
interaction with means at baseline being 11.12 errors, to size reversal with 33.2 errors and
then black/white discrimination with 32.3 errors (P < 0.0001)(Figure 1C). For the black/
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white reversal task the E/C group differs from the other three groups while the C/V group
also differs from E/V and C/C, which do not differ from one another. These results suggest
that there was impairment in reversal learning in the dogs receiving the vaccine alone, which
was ameliorated with the addition of behavioral enrichment. Further, the dogs receiving the
behavioral enrichment alone had the lowest average error scores.
Spatial Acquisition and Memory

Author Manuscript

Once dogs had been treated for 11.9 months or for 18.1 months (Table 2), they were tested
on the 3-choice spatial memory task where the delays of 20, 70 or 110 seconds could occur
on a single day. Only dogs that were able to complete all the testing across the 2 time points
were included in the analysis. Neither treatment alone or when combined resulted in
improved spatial memory. To detect any changes in spatial memory as a function of
treatment over the 18 months of the study, a repeated measures analysis was used for each
delay interval separately (20, 70, 110s). At the 20 second delay (F(2,36)=16.12 p<0.0005),
the 70 second delay (F(2,36)=5.51 p=0.008) and the 110 second delay (F(2,36)=17.32
p<0.0005) there was an overall decrease in accuracy over time suggesting an aging effect.
There was no apparent maintenance of spatial memory over time as a function of treatment
or an effect of the combined treatment (data not shown).
CSF Aβ

Author Manuscript

For CSF Aβ outcome measures, only animals that completed over 18 months of the
treatment protocol and where CSF samples were acquired at every time point were included
(n=21; C/C-7, E/C-4, C/V-5, E/V-5). None of the effects in the linear mixed model (LMM)
for CSF Aβ40, namely, the main effect due to VAC or ENR, the interaction between VAC
and ENR, the main effect due to time, and the interactions between time and VAC, time and
ENR, or time, VAC and ENR are significant (P >0.11 for each effect).
However, for CSF Aβ42 (Figure 2A) there is a significant main effect due to the VAC (P =
0.01) in that the adjusted mean CSF Aβ42 level in the presence of VAC is 134.4 pmol ± 7.1,
which is higher than CSF Aβ42 measures in the absence of the VAC (104.7 ± 7.6). None of
the other effects in the LMM are significant (P > 0.12) although there is a hint of an
interaction between VAC and ENR. The increased CSF Aβ42 VAC effect appears to be
associated with the presence of ENR (ENR with no VAC at 92.9 ± 12.5 and with VAC at
139.8 ± 9.8). This is in contrast to CSF Aβ42 in groups with no VAC at 116.5 ± 8.7 versus
those with the VAC at 129.0 ±10.3 in the absence of ENR, indicating a much smaller VAC
effect (P = 0.12 for the interaction between ENR and VAC).

Author Manuscript

Brain Aβ
We hypothesized that the levels of Aβ1–40 and Aβ 1–42 in the brain would be reduced due
to the vaccine as we reported previously (Head, et al., 2008) and possibly further reduced
with the presence of behavioral enrichment. As a first test of this hypothesis we measured
the extent of plaques containing Aβ42, total Aβ (using 6E10 Aβ1–16), and pyroglutamate
Aβ in the PFCTX, PCTX and OCTX by immunohistochemistry. For these analyses we used
an ANOVA with a 2 x 2 factorial design with factors VAC (yes/no) and ENR (yes/no) to
compare mean responses.
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Aβ42 plaque load was significantly decreased as a result of VAC (both C/V and E/V groups)
in the PFCTX (p<0.01), OCTX (p=0.01), and PCTX (p=0.03) (Figure 2B). No additive
effects were seen between the VAC and ENR in reducing Aβ42 plaque load in any brain
region sampled. Representative examples of immunolabeling in the prefrontal cortex for
each treatment group are shown in Figures 2E–H. Total Aβ (6E10) plaque load was reduced
by the VAC in all brain regions (PFCTX, p<0.01; OCTX, p=0.03; PCTX, p=0.04) (Figure
2C). No additive effects were detected in the combination treatment group in decreasing
total Aβ plaque loads in any of the brain regions sampled. Previous immunotherapy studies
have not evaluated effects of an anti-fibrillar Aβ1–42 vaccine on post-translationally
modified Aβ. Since post-translationally modified Aβ, more specifically AβpE3, is
considered to be a more toxic and chronobiologically older form of Aβ, we tested our
vaccine on its ability to reduce this form of Aβ. We hypothesized that VAC would
significantly reduce AβpE3 plaque loads in all regions examined. AβpE3 plaque loads were
decreased only in PFCTX (p=0.01) but not PCTX or OCTX (Figure 2D). No main effects of
the ENR or an ENR by VAC interaction were observed.
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As a second test of this hypothesis and to confirm reductions in Aβ plaque loads, we
measured PBS, SDS, and FA extracted Aβ 1–40 and Aβ 1–42 by sandwich ELISA (Figure
3). For these analyses we used an ANOVA with a 2 x 2 factorial design with factors VAC
(yes/no) and ENR (yes/no) to compare mean responses. There was a significant amount of
individual variability in the amounts of Aβ measured and no treatment effects were observed
for either Aβ40 (Figure 3A) or Aβ42 (Figure 3D) extracted from the PBS soluble fraction.
In SDS extracted Aβ42 (Figure 3B), there was a significant main effect of the VAC with
reduced levels in the PFCTX and OCTX (p<.05) but not in Aβ40 (Figure 3E). FA extracted
Aβ42 (Figure 3C) was decreased in the PFCTX, PCTX and OCTX consistent with plaque
load outcomes; FA extracted Aβ40 (p=0.01) in the PFCTX and Aβ42 (p=0.01) extracted
from PFCTX, PCTX and OCTX was decreased in VAC dogs but not ENR dogs and there
was no interaction between the two treatments. The OCTX also showed evidence of reduced
FA extracted Aβ42 in the ENR group (p=0.01), the VAC group (p=0.02) as well as an
interaction with in the combination group (p=0.03). This interaction effect appears to result
in less of an Aβ42 reduction for combination treatment group animals relative to dogs
provided with the VAC alone.
Comparison of Aβ Plaque Loads of Study Dogs to Pretreatment Brains

Author Manuscript

The PFCTX had lower Aβ42 plaque loads due to ENR that trended towards significance. In
addition, although no ENR effect was seen statistically in lowering total Aβ plaque loads in
the PFCTX and PCTX, the E/C treatment group did have significantly lower loads than the
C/C group. It is unclear if these lower plaque loads were due to a clearance of pre-existing
Aβ or maintenance of Aβ pathology at the same level that was present at the start of
treatment by the ENR. To investigate this further, we used PFCTX and PCTX tissue of
archive cases that were age-matched to study cases at their baseline age and immunostained
them for Aβ42 (10/10 animals were positive based on a cut off of 1% load), total Aβ (10/10
positive) and AβpE3 (1/10 positive). The results provided measurements that represented the
Aβ plaque loads of the study cases at baseline before treatment began. The Aβ loads
obtained from this archival group are also shown in Figure 2B, C and D.
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In the PFCTX, significant group effects were seen in the reduction of Aβ42 (p<0.001), total
Aβ (p<0.001), and AβpE3 (p=0.009) plaque loads between the pre-treatment group to the
study treatment groups. The pre-treatment group had significantly lower Aβ42 (p=0.050)
and total Aβ (p=0.014) plaque loads than the C/C group indicating an increase in plaque
loads with age. The plaque loads of the pre-treatment group did not statistically differ from
the E/C group, suggesting a maintenance effect due to the ENR (p<.05). Similar results were
observed in the PCTX. A significant group difference was noted when comparing Aβ42
(p=0.003), total Aβ (p=0.021), and AβpE3 (p=0.020) plaque loads between the pretreatment group to the study treatment groups in the PCTX (Figures 2B,C,D). As seen in the
PFCTX, the pre-treatment group Aβ42 plaque load did not differ significantly from the E/C
group in the PCTX, again suggesting that ENR was likely maintaining Aβ42 plaque loads at
levels that were in the brain 2 years prior.
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Treatment Effects on Microhemorrhages

Author Manuscript

Based on previous studies in transgenic mice (Pfeifer, et al., 2002;Racke, et al.,
2005;Wilcock and Colton, 2009;Wilcock, et al., 2007;Wilcock, et al., 2004) and human
clinical trials (Uro-Coste, et al., 2010), we hypothesized that the two VAC groups may have
more microhemorrhages than those animals receiving no VAC. The total number of bleeds
across all brain regions sampled ranged between 0 and 23 and we used a Kruskal-Wallis test
to compare the groups. The most bleeds were seen in the PFCTX having a range from 1 to
10 bleeds, with the exception of one dog having 17 bleeds (representative examples are
provided in Figure 4B, C, D). This canine in particular was a female, started the study at the
age of 11.6 years, and was in the E/C treatment group. The OCTX had bleed counts ranging
from 0 to 7. Neither ENR (H(1)=0.025 p=0.876) nor VAC (H(1)=0.350 p=0.554)
significantly increased microhemorrhage frequency in the PFCTX (Figure 4A). In the
OCTX, there was a statistically significant overall increase in microhemorrhages due to the
VAC (H(1)=6.501 p=0.011) (C/V and E/V groups - Figure 4A,D). Interestingly, fewer
microhemorrhages were detected in the E/C animals in the OCTX compared to C/V animals
(Figure 4A). It is possible that this decrease in microhemorrhages of the E/C group (non
VAC animals) could have led to the statistically apparently higher frequency of
microhemorrhages due to the VAC.
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With the observation that E/C group had fewer microhemorrhages in the OCTX compared to
the other treatment groups and C/C group, we wanted to determine whether ENR was
reducing the number of microhemorrhages or having a maintenance effect as observed with
plaque loads. To do this we used the same 10 archive cases used for plaque load analysis that
were age-matched to study dogs at the start of the study (10.5–13.6 years) (pre-treatment).
The total number of microhemorrhages in the PFCTX from this pre-treatment group of dogs
ranged from one to eight, similar to numbers in the treatment groups and control group.
Statistically, there was no group difference in microhemorrhage counts in the PFCTX
between the pre-treatment group and the four study groups (χ2(4)=1.103 p=0.894) (Figure
4A). In the OCTX, pre-treatment dogs only showed 0 to 3 microhemorrhages compared to
the 0 to 7 range seen in the study dogs. There were significantly different microhemorrhage
counts between the groups (the four study groups 2(4)=15.400 p=0.004). The pre-treatment
group showed approximately the same number of microhemorrhages as the E/C treatment

Neurobiol Aging. Author manuscript; available in PMC 2018 January 01.

Davis et al.

Page 15

Author Manuscript

group (Figure 4A). While the C/C, C/V, and E/V treatment groups were not different in
number of microhemorrhages, they generally were higher than the pre-treatment and E/C
groups. This would suggest that the E/C treatment was having a maintenance or protective
effect against microhemorrhages in the OCTX while all other treatment groups experienced
more microhemorrhages with age independently of the VAC.
Brain derived neurotrophic factor as a function of treatment

Author Manuscript

We next tested the hypothesis that brain derived neurotrophic factor (BDNF) RNA levels
would be increased in dogs provided with ENR and possibly further increased when
combined with Aβ clearance with the vaccine. Figure 5 shows that relative to the C/C group,
the parietal cortex of the C/V group had increased BDNF mRNA (~1.4 fold) that were not
significant but the combination treatment (E/V) was associated with a significant increase in
BDNF mRNA level (1.6 fold). The E/C group was not different from the CC group (~0.7
fold). No systematic differences in the occipital cortex were observed in BDNF mRNA level
(data not shown).

Discussion

Author Manuscript

The current study hypothesized that aged dogs with pre-existing Aβ pathology vaccinated
with fibrillar Aβ1–42 would show reduced Aβ neuropathology as observed previously, but
also improved cognition if the vaccine was combined with behavioral enrichment.
Consistent with previous studies in aged dogs, the active Aβ vaccine alone did not improve
cognition (Head, et al., 2008). As hypothesized, dogs in the combination treatment group
showed a slowing in cognitive decline on a measure of visual discrimination learning. The
addition of ENR on the vaccine was particularly striking on a measure of executive function
(reversal learning). We observed impaired function in dogs provided with the VAC alone that
was significantly improved with the addition of ENR. Brain Aβ was reduced with the VAC
in the current study similar to our previous report (Head, et al., 2008). BDNF mRNA levels
were increased significantly in dogs provided with the combination treatment, providing a
possible mechanism underlying cognitive improvements and similar to a previous study of
the combination effects of behavioral enrichment with an antioxidant diet (Fahnestock, et al.,
2010). Interestingly, there were several unexpected findings in the current study. First, ENR
resulted in less brain Aβ on a subset of the brain regions sampled, consistent with some but
not all AD mouse model studies (Lazarov, et al., 2005) but novel with respect to canines
(Pop, et al., 2010). Second, ENR may slow cerebrovascular pathology in aging dogs, which
may have significant clinical implications for trials testing immunotherapy in patients with
AD. A summary of the outcome measures are provided in Table 3.
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Effects of the VAC on aging dogs
Cognition—We had previously published the results of an Aβ vaccine in aging dogs
showing no improvements in learning and memory, but evidence of a maintenance of
function on an executive function task (reversal learning) (Head, et al., 2008). We observed
some similar and yet interesting differences in the current study. There was no evidence of
an improvement in learning or memory in VAC dogs, similar to our previous report (Head, et
al., 2008). This contrasts with another study of pet dogs (6–18 years, differing breeds) with
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cognitive dysfunction syndrome that showed rapid improvements in cognition in response to
active Aβ immunotherapy (Bosch, et al., 2013). It is interesting that in the Bosch et al., study
that the authors used Aβ40 or Aβx-40 peptides as the immunogen in contrast to the current
study using fibrillar Aβ1–42. Despite these differing approaches, the mechanism underlying
rapid cognitive improvements in one study and slower decline in the current study have yet
to be determined.
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We also found that dogs receiving the VAC alone showed impaired executive function that
evolved after 16 months of treatment. Interestingly, this was ameliorated with the presence
of ENR as will be discussed shortly. This was unexpected given our previous work showing
that the same vaccine slowed reversal learning deficits over time (Head, et al., 2008). When
comparing the two studies, dogs in our previous study were between 9.3 and 9.5 years of age
when treatment was initiated, whereas in the current study, dogs were 11.5 to 11.9 years of
age. Thus, an earlier intervention resulted in benefits to executive function that could not be
elicited in the older animals unless combined with behavioral enrichment.
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Aβ Neuropathology—Active Aβ vaccination and passive immunotherapy studies show
positive results in reducing Aβ plaque pathology in both animal models and patients with
AD (DeMattos, et al., 2001;Head, et al., 2008;Release, 2012;Salloway, et al., 2014;Salloway,
et al., 2009;Schenk, et al., 1999;Silverman, 2012;Teich, 2012). VAC in dogs reduces brain
Aβ42 measured by plaque load and both Aβ40 and Aβ42 measured biochemically in the
insoluble FA fraction as reported previously (Head, et al., 2008). These results are also
similar to another report of immunotherapy with Aβ in dogs showing reduced Aβ plaque
pathology (Neus Bosch, et al., 2015). Novel outcomes of the current study indicate first, that
PBS soluble Aβ in the brain was not reduced, suggesting the VAC did not change Aβ
production per se. SDS soluble Aβ42 was reduced in response to the VAC but not Aβ40.
Post-translationally modified Aβ, including AβpE3, is toxic and involved in the initial stages
of the disease thereby making it a crucial therapeutic target for clearance in a clinical setting
(Alexandru, et al., 2011;He and Barrow, 1999;Russo, et al., 2002;Schilling, et al.,
2006;Schlenzig, et al., 2009;Wirths, et al., 2009). In the current study, AβpE3 was cleared in
VAC dogs, particularly in the prefrontal cortex. This outcome is promising for human
clinical trials given that a significant amount of Aβ is post translationally modified and
thought to be highly aggregated and less amenable to clearance in dog (Azizeh, et al.,
2000;Chambers, et al., 2011;Frost, et al., 2013;Schmidt, et al., 2015) and human brain
(Azizeh, et al., 2000;Fonseca, et al., 1999;Frost, et al., 2013). Last, CSF Aβ42 was increased
in dogs receiving the VAC suggesting clearance from the brain parenchyma that could be
detected peripherally. An inverse correlation between CSF and brain Aβ has been reported
in humans (Blennow, et al., 2015;Strozyk, et al., 2003) and dogs (Head, et al., 2010)
suggesting that as brain Aβ deposits it is depleted from the CSF (DeMattos, et al., 2002).
Thus, CSF levels of Aβ42 may serve as a useful noninvasive outcome measure to detect
beneficial effects of immunotherapy on brain Aβ.
Microhemorrhages—Because previous human clinical trials using active vaccination
with fibrillar Aβ1–42 was associated with several cases of meningoencephalitis (Gilman, et
al., 2005;Hock, et al., 2003), passive immunization is currently being investigated in mild to
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moderate AD. This passive immunotherapy approach also reduces Aβ pathology and leads
to modest reductions in rates of cognitive decline (Doody, et al., 2014;Doody, et al.,
2014;Salloway, et al., 2014;Salloway, et al., 2014). Passive immunotherapies, however, lead
to microhemorrhages in mouse models (Wilcock, et al., 2004) and in human clinical trials
(Sperling, et al., 2012). The presence of microhemorrhages could increase risk of further
cognitive impairment (Blitstein and Tung, 2007;Viswanathan and Chabriat, 2006). Thus, we
also measured the extent of microhemorrhages in VAC animals and noted an increase in
microhemorrhages in the occipital cortex, but not prefrontal cortex suggesting canines can
provide a useful model to detect adverse outcomes in response to immunotherapy.
Effects of ENR on aging dogs
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Cognition—Dogs provided with ENR in our previous studies showed improved
cognition(Milgram, et al., 2002), maintenance of cognition and improved memory (Cotman,
et al., 2002;Milgram, et al., 2005). However, ENR dogs we described previously did not
show reduced brain Aβ suggesting that the mechanism of action was independent of Aβ
deposition (Pop, et al., 2010). Interestingly, we did not observe similar outcomes in the
current study: ENR dogs did not show improved cognition, nor maintenance of cognition.
This outcome was unexpected as our previous research suggested that ENR was a robust
means to improve cognitive function in dogs (Costa, et al., 2006;Cotman and Head,
2008;Lazarov, et al., 2005). The reasons for this may be two-fold. First, dogs in the previous
study were younger when treatment was started and as such, may have been more responsive
to the enrichment protocol whereas the older animals in the current study did not show the
same benefits. Second, standard housing-enrichment programs have matured from earlier
studies such that an ENR threshold may have been met between all treatment groups and
further benefits did not occur with the additional environmental enrichment and cognitive
training that was provided in this study. It is possible the lack of consistent pair housing as
compared to single housing used previously may have led to larger cognitive benefits than
observed here (Milgram, et al., 2005). Alternatively, our previous study may have revealed
that singly housed dogs were impoverished relative to the pair housed animals. A more
intensive program may be required for future treatment studies.
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Aβ Neuropathology—Novel findings in the current study relate to the effects of ENR on
Aβ deposition. In our previous ENR study in canines we did not observe a reduction in Aβ
pathology after over 2 years of treatment (Pop, et al., 2010). However, in the current study,
we observed ENR led to reduced total Aβ plaque loads, similar to previous reports in
transgenic mouse models of AD (Costa, et al., 2006;Lazarov, et al., 2005). Reduced plaque
loads in response to ENR in the current study may indicate a prevention benefit. Lower
plaque loads in ENR animals may be due to a slowing of Aβ accumulation. Tissue samples
from dogs that were the same age as animals at the start of the study allowed us to estimate
the extent of Aβ at baseline. The pre-treatment dogs exhibited significantly lower plaque
loads than control dogs for all types of Aβ examined illustrating the increase of plaque loads
in the canine with age over the ~ 2 year period of time. Further, the pre-treatment dog Aβ
plaque pathology most closely resembled that of the E/C treatment group suggesting that
ENR led to maintenance of plaque load in treated dogs rather than a clearance/reduction of
existing Aβ plaques. The results of the studies with AβpE3 confirm and extend this
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interpretation. AβpE3 plaque loads were not reduced in dogs that received ENR suggesting
that pre-existing plaque pathology was not cleared, in contrast to the VAC dogs. The
mechanism by which Aβ is reduced in dogs provided with ENR has yet to be explored but
previous studies argue against changes in alpha-secretase activity and total APP (Pop, et al.,
2010).
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Microhemorrhages—As described previously, microhemorrhage frequency was
increased in the occipital cortex due to the VAC. However, the ENR dogs had a significantly
lower number of microhemorrhages. By comparing ENR (E/C) animals to pre-treatment
brain samples, we found that dogs that were 2 years younger showed a similar number of
microhemorrhages in the OCTX as the E/C treatment group. This observation suggests that
ENR may protect from age-associated increases in microhemorrhages. Similar
cerebrovascular benefits have been reported in transgenic mouse models of AD (Herring, et
al., 2008).
Synergist Effects of Combining ENR with VAC
The overarching goal of the study was to test the hypothesis that the combination of ENR
and VAC would lead to cognitive benefits and reduced brain pathology. To some extent, our
hypothesis was supported and yet in other aspects, refuted. As expected, dogs receiving the
VAC developed anti-Aβ1–42 titers over time.
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In terms of cognitive outcomes, the results were modest. We observed that dogs receiving
the combination treatment showed a significant maintenance of learning on a series of visual
discrimination tasks that was larger than either ENR or VAC alone. The ENR also appears to
ameliorate executive dysfunction in VAC only treated dogs although it cannot improve dogs
to levels observed in the ENR condition alone. However, none of the treatments improved
memory. The combination treatment group showed significantly reduced prefrontal, and
parietal and in some cases occipital Aβ in terms of plaque loads, posttranslationally
modified Aβ, and insoluble Aβ although not lower than the VAC alone. Given that the VAC
essentially cleared Aβ plaques, it is not surprising we could not detect further reductions.
However, the benefits of ENR on reducing microhemorrhages could not be observed with
the combination treatment suggesting that the VAC drives this pathology to a greater extent
than ENR counteracting the effect. The implications of our observation of increased
numbers of microhemorrhages in the VAC group are that the response of aging dogs to the
vaccine is similar (and possibly predictive) of human clinical trials outcomes and also
suggests a common pathological mechanism.
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Another novel outcome to the current study involved the measures of BDNF mRNA. BDNF
is a critical growth factor supporting neuron and synapse health (Ando, 2002;Lu, et al.,
2008), and is reduced in AD transgenic mice and in human AD brain (Holsinger, et al.,
2000;Intlekofer and Cotman, 2013;Michalski and Fahnestock, 2003;Poon, et al., 2011).
BDNF levels can be increased in by physical activity (Cotman, et al., 2007;Intlekofer and
Cotman, 2013) and by environmental enrichment (Wolf, et al., 2006;Zajac, et al., 2010). In
dogs, aging is associated with significantly reduced BDNF mRNA in temporal cortex that
can be improved when animals are provided with a combination of behavioral enrichment
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and an antioxidant diet (Fahnestock, et al., 2010). To determine if downstream pathologies
associated with Aβ may be modified with behavioral enrichment or in vaccinated dogs, we
measured RNA levels of BDNF. In the current study we found that BDNF mRNA was
increased in vaccinated dogs and significantly increased in the combination group. Thus,
reducing Aβ may be linked to increased BDNF and may in part, be associated with the
cognitive maintenance observed in the current study.
Conclusions

Author Manuscript

Behavioral enrichment slows Aβ accumulation and reduces the rate of microhemorrhages,
while an Aβ vaccine clears pre-existing Aβ pathology including post-translationally
modified Aβ.The combination treatment maintained visual discrimination learning over ~19
months suggesting a slowing of cognitive decline. Several clinical trials are underway that
are assessing lifestyle modifications including exercise and cognitive training in
nondemented elderly (for a review see (Solomon, et al., 2014)). Aged canines may represent
an early AD phenotype (Cotman and Head, 2008) that is associated with selective
hippocampal neuron losses (Siwak-Tapp, et al., 2008). The combination treatment approach
described in this experiment may be more efficacious if implemented prior to significant
cognitive decline and Aβ deposition that occurs in dogs beginning around 6–8 years
(Cotman and Head, 2008). However, it is exciting to note that even in animals with extensive
Aβ deposition and cognitive dysfunction that benefits could be elicited, which is promising
for patients with mild-moderate AD. In the future, prevention studies using a combination
therapy approach in middle aged dogs may result in memory maintenance, and including
imaging techniques that enable us to visualize cerebrovascular benefits will be helpful.
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Highlights for Review
•

Aβ immunotherapy in aged canines leads to reduced brain Aβ

•

Aβ immunotherapy increased microhemorrhages and impaired
executive function

•

Behavioral enrichment improved executive function over time

•

A combination of Aβ vaccination with behavioral enrichment leads to
cognitive maintenance

•

A combination reduced brain Aβ, increased BDNF and increased
microhemorrhages.
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Figure 1.

Author Manuscript

Effects of the anti-Aβ1–42 vaccine on antibody titers and cognition over time. Anti-fibrillar
Aβ1–42 IgG responses increased and were maintained over time in groups receiving the
vaccine (A)(*p<.05 between VAC (n=12) and non VAC (n=11)). To detect treatment effects
from all 4 groups over time, a discrimination task (B) was used. Discrimination learning
error scores increased over time suggesting both increased task difficult and an underlying
aging process (B). The combination treatment group (E/V (n=7 completers)) performed the
best overall (*p<.05) and showed slower decline than either treatment alone. (C) Reversal
learning was associated with the E/C (n=4 completers) group having the lowest errors scores
over time overall suggesting a maintenance of cognition (*p<.05). Interestingly, the C/V
(n=3 completers) group had the highest error scores overall but this was ameliorated by the
presence of ENR (**p<.05) such that the E/V (n=7 completers) group was similar to the C/C
(n=7 completers) group. Error bars represent standard errors of the mean.
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Figure 2.
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CSF and brain Aβ changes with treatment. (A) CSF Aβ1–42 was significantly higher in the
dogs receiving the VAC at 12 months of treatment (n=17) and at the end of the study (n=14)
(*p<.05). (B) Aβ42 plaque loads were variably affected depending on the brain region
sampled. In the PFCTX cortex, the C/C (n=8) group had significantly higher Aβ42 than the
pretreatment group (n=10), and the pretreatment group was significantly higher, in turn, than
both groups that received the VAC (C/V (n=8) and E/V (n=8) (#p<.05 when comparing the
pretreatment group to other groups). The pretreatment Aβ42 loads were similar to the ENR
only condition (E/C) suggesting a halting of Aβ42 deposition. In both the PFCTX and the
PCTX, the C/C group had significantly higher Aβ42 loads than the C/V and E/V groups
(*p<.05). However in the PFCTX, there was an additional reduction in Aβ42 plaque load in
the E/C group relative to C/C (*p<.05 when comparing C/C to other groups) but not in the
parietal or occipital cortex. A similar trend was observed in the OCTX but these differences
did not reach statistical significance (note – there were no data from the pretreatment group
for this brain region). (C) 6E10 plaque loads were also variably affected depending on the
brain region sampled. In the PFCTX cortex, the C/C group had significantly higher 6E10
loads than the pretreatment group (#p<.05 when comparing the pretreatment group to other
groups). The pretreatment 6E10 loads were similar to all other treatment groups. In the
PFCTX, the C/C group had significantly higher 6E10 loads than the C/V and E/V groups
(*p<.05 when comparing C/C to other groups). A similar trend was observed in the PCTX
and the OCTX but these differences did not reach statistical significance (note – there were
no data from the pretreatment group for the OCTX region). (D) AβpE3 plaque loads were
variably affected depending on the brain region sampled. In the prefrontal cortex, the C/C
and the E/C group had significantly higher AβpE3 than the pretreatment group ( #p<.05
when comparing the pretreatment group to other groups). In the PFCTX, the C/C group had
significantly higher AβpE3 loads than the C/V and E/V groups (*p<.05 when comparing
C/C to other groups). A similar pattern was observed in the PCTX and the OCTX but these
differences did not reach statistical significance (note – there were no data from the
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pretreatment group for OCTX region). Representative Aβ immunostained sections
(representing the average % load for each group) from the PFCTX showing reduced
pathology relative to the C/C group (E) in the E/C (F), C/V (G), and E/V (H).
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Figure 3.

PBS, SDS and FA extracted Aβ1–40 and Aβ1–42 as a function of treatment and brain
region. PBS (A), SDS (B) and FA (C) extracted Aβ1–42 was significantly decreased in dogs
receiving the vaccine (n=18) relative to those not vaccinated (n=16) primarily in the PFCTX
and OCTX. The PCTX did not show significant changes. In PBS (D), SDS (E) and FA (F)
extracted Aβ1–40 measures, fewer differences were noted except the vaccine led to
significant decreases in PFCTX and OCTX Aβ1–40 in the FA fraction. Bars indicate group
averages, error bars are standard errors of the mean. Lines with * indicate significant group
differences in the VAC group from the non vaccine group at the p<.05 level.
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Figure 4.

An Aβ vaccine increases the frequency of microhemorrhages. The average frequency of
microhemorrhages was unchanged in the PFCTX. However, in the OCTX there were
increased mean numbers of microhemorrhages in both groups of vaccinated dogs (n=18)
(*p<.05) as compared with the C/C dogs (A). Untreated aged dogs (n=8) had more
microhemorrhages than dogs 2 years younger (n=10) (**p<.05). Dogs provided with
behavioral enrichment only (E/C (n=18) had an equivalent number of microhemorrhages
compared with dogs 2 years younger. Error bars represent standard errors of the mean.
Examples of Prussian blue staining in the B. PFCTX of a dog in the E/V group at lower
magnification showing microhemorrhages (arrows) and C. higher magnification (arrows). D
shows a blood vessel with a microhemorrhage in the OCTX of a dog receiving the vaccine
alone (arrows).
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Figure 5.

Parietal BDNF mRNA levels as a function of treatment. Dogs provided with either the Aβ
vaccine alone (n=8) or in combination with behavioral enrichment (n=10) show significantly
increased levels of parietal BDNF mRNA than untreated animals (*p<.05). Dogs provided
with only behavioral enrichment (n=8) are not significantly different from controls (n=8).
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8

8

8

10

C/C

E/C

C/V

E/V

138.2 (3.5)

138.8 (3.8)

142.7 (2.6)

139.9 (2.4)

Age at Start

Data are presented as means (SE)

N

162.5 (3.2)

163.8 (4.1)

162.6 (3.1)

165.8 (2.4)

Age at Death

7

5

5

5

Number Singly Housed
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Group

5/5

5/3

5/3

5/3

Sex (F/M)
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Study timeline
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Cognitive Task

Time on Treatment (months)

Number of Injections

Baseline Discrimination Learning

0

0

Baseline Discrimination Reversal

0

0

Spatial Maximal Memory

0

0

Spatial Memory

0

0

Landmark Discrimination*

1

2

Oddity Discrimination*

4.3

5

Size Discrimination and Reversal

7.6

10

T1 Spatial Maximal Memory

9.4

11

T1 Spatial Memory

11.9

14

T2 Landmark Discrimination*

15.2

18

Black/White Discrimination and Reversal

16.1

19

T2 Spatial Memory

18.1

21

Brain Tissue Harvested

19.6

23

*

tasks given to the behavioral enrichment group animals only.
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Summary of outcome measures*

Cognition

Outcome Measure

E/C

C/V

E/V

Aβ antibody titers

N/C

Increased

Increased

Landmark Discrimination

N/C

N/A

N/C

Oddity Discrimination

N/C

N/A

N/C

Repeated Visual Discrimination

N/C

N/C

Improved

Repeated Reversal Learning

Improved

Impaired

N/C

Spatial Memory

N/C

N/C

N/C

CSF Aβ1–40

N/C

N/C

N/C

CSF Aβ1–42

Decreased

Increased

Increased

Prefrontal

Decreased

Decreased

Decreased

Parietal

N/C

Decreased

Decreased

Occipital

N/C

Decreased

Decreased

Prefrontal

N/C

Decreased

Decreased

Parietal

N/C

Decreased

Decreased

Occipital

N/C

Decreased

Decreased

Prefrontal

N/C

Decreased

Decreased

Parietal

N/C

N/C

N/C

Occipital

N/C

N/C

N/C

PBS soluble Aβ1–42

N/C

N/C

N/C

PBS soluble Aβ 1–40

N/C

N/C

N/C

Prefrontal

N/C

Decreased

Decreased

Parietal

N/C

N/C

N/C

Occipital

N/C

N/C

N/C

N/C

N/C

N/C

Prefrontal

N/C

Decreased

Decreased

Parietal

N/C

Decreased

Decreased

Occipital

Decreased

Decreased

Decreased

Prefrontal

N/C

Decreased

Decreased

Parietal

N/C

N/C

N/C

Occipital

N/C

N/C

N/C

CSF
Aβ1–42 Plaques

Author Manuscript

Aβ total (6E10)
A β Plaques

AβpE3 Plaques

Author Manuscript

SDS soluble Aβ1–42

SDS soluble Aβ1–40
Aβ ELISA

FA soluble Aβ1–42

FA soluble Aβ1–40
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Microhemorrhages
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E/C

C/V

E/V

Prefrontal

N/C

N/C

N/C

Occipital

N/C

Increased

Increased

N/C

Increased

Increased

Growth Factor (BDNF)

*

Increases/decreases were statistically significantly different from the C/C group. N/C – no change from C/C group N/A – not applicable
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